• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Canary Foundation receives $8.5M to advance cancer early detection studies

Canary Foundation receives $8.5M to advance cancer early detection studies

August 23, 2012
CenterWatch Staff

Canary Foundation, a cancer-focused non-profit based in Palo Alto, Calif., has received two contributions totaling $8.5 million to advance Canary’s goal of developing cancer early detection diagnostic tools.

The first gift, $7.5 million, is from the William K. Bowes Jr. Foundation to support a faculty position focused on clinical trials at the Canary Center at Stanford.  The management of the clinical trial process is a growing need at the center with requirements ranging from the approval process for patient studies, storing and testing samples from current clinical trials and growing the center's ability to support current and future clinical trials. The gift will also provide funds for the Founder's Fund that supports unmet needs and special projects.

The second donation of $1 million is from the Frank and Denise Quattrone Foundation and supports the Prostate Active Surveillance Study (PASS). A clinical trial involving 1,000 men, PASS is looking for ways to distinguish lethal versus non-lethal prostate cancer.  This gift is timely as the prostate cancer science team moves deeper into the trial, providing funds to complete the enrollment of men, gather and test samples and develop important industry partners.

"These contributions create new momentum for our research," said Ronica Smucker, executive director of Canary Foundation. "Moving the studies out of the lab and to patients, with FDA approval, helps prove the efficacy of the blood and imaging tests we are developing that can save lives on a widespread basis. The support of these foundations brings Canary's mission to a whole new level."

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing